Time filter

Source Type

Xaubet A.,Servicio de Neumologia | Xaubet A.,CIBER ISCIII | Ancochea J.,Hospital Universitario Of La Princesa | Bollo E.,Complejo Asistencial Universitario | And 7 more authors.
Archivos de Bronconeumologia | Year: 2013

Idiopathic pulmonary fibrosis is defined as a chronic fibrosing interstitial pneumonia limited to the lung, of unknown cause, with poor prognosis and few treatment options. In recent years there has been an increase in their prevalence, probably due to the optimization of diagnostic methods and increased life expectancy. The ATS/ERS Consensus (2000) established the diagnostic criteria and recommendations for the assessment of the disease course and treatment. Later studies have helped to redefine diagnostic criteria and treatment options. In 2011, an international consensus was published, establishing diagnostic criteria and new treatment strategies. These guidelines have been updated with the newest aspects of diagnosis and treatment of idiopathic pulmonary fibrosis. A level of evidence has been identified for the most relevant questions, particularly with regard to treatment options. © 2012 SEPAR.

Rodriguez L.M.,Servicio de Pediatria | Robles B.,National Health System | Marugan J.M.,Hospital Clinico Universitario | Suarez A.,Gerencia de Atencion Primaria | Garcia Ruiz De Morales J.M.,Complejo Asistencial Universitario
Indian Journal of Pediatrics | Year: 2013

Objective To investigate if serum C-reactive protein (s-CRP) and interleukin 6 (s-IL6) provide information for predicting renal damage and for DMSA patient selection in children with urinary tract infection (UTI). Methods This observational study was carried out in children with UTI. s-CRP and s-IL6 were measured at UTI diagnosis. Patients forming renal scarring were identified by DMSA scans. The usefulness of s-CRP and s-IL6 measurements for nephropathy scarring diagnosis was evaluated using diagnostic quality and efficiency indexes. Results Thirty-two children were included in the study. Eight showed renal scarring after the follow-up. The s- CRP was 110.23±59.69 mg/L and 52.46±63.13 mg/L for patients with and without renal scarring. The s-IL6 concentration was 18.34±11.80 pg/mL and 8.07±9.51 pg/mL respectively. The cut-off points for optimum nephropathy scarring diagnosis were 115 mg/L for s-CRP and 20 pg/mL for s-IL6. The value of highest sensitivity for s-CRP was >5 mg/L (S:100 %) and greatest specificity was >150 mg/L (Sp:95.83). The highest sensitivity for s-IL6 was >4 pg/mL (S:100 %) and the maximum specificity was >40 pg/mL (Sp:100 %). Conclusions Results confirm that children who will develop renal scarring show higher levels of s-IL6 and s-CRP at UTI diagnosis. However, none of the techniques provide sufficient information for predicting renal damage in all patients and for DMSA patient selection. © Dr. K C Chaudhuri Foundation 2013.

Cubo E.,Complejo Asistencial Universitario | Cubo E.,CIBER ISCIII | Benito-Leon J.,University Hospital 12 Of Octubre | Benito-Leon J.,CIBER ISCIII | And 5 more authors.
Neuroepidemiology | Year: 2012

Objective: Little is known about apathy in the early stages of Parkinson's disease (PD). We determined the clinical correlates of apathy in a large representative sample of patients recently diagnosed with PD (ANIMO study). Methods: PD patients, diagnosed within 2 years of inclusion, were recruited in 102 outpatient clinics situated in 82 populations throughout Spain. Apathy was quantified using the Lille Apathy Rating Scale (LARS). Clinical comparisons and correlations were performed using nonparametric tests. Regression analyses were used to test the association of clinical variables with apathy. Results: We recruited 557 PD patients (60.3% men) with a mean age of 68.8 ± 9.7 years, and UPDRS motor score of 21.1 ± 10.8. Apathy only was diagnosed in 186 (33.4%), and apathy and depression in 215 patients (38.6%). Patients with higher comorbidity (OR = 1.10, 95% CI 1.01-1.20, p = 0.001), motor impairment (OR = 1.07, 95% CI 1.03-1.10, p < 0.0001), and lower education (OR = 2.16, 95% CI 1.21-3.85, p = 0.009) had higher odds of having apathy, in contrast to patients living in a rural environment (OR = 0.35, 95% CI 0.32-0.85, p = 0.01), and left predominant PD motor laterality (OR = 0.34, 95% CI 0.13-0.88, p = 0.01). LARS scores were significantly correlated with UPDRS motor scores (r s = 0.44, p < 0.001), predominantly with axial score (r s = 0.43, p < 0.001). Conclusions: In PD, apathy is a very common and disabling nonmotor symptom separable from depression. Patients living in a rural environment, with lower comorbidity and motor impairment, higher education background, and left predominant PD motor laterality are at lower risk of suffering from apathy. Copyright © 2012 S. Karger AG, Basel.

Alvarez-Lario B.,Complejo Asistencial Universitario | Macarron-vicente J.,Complejo Asistencial Universitario
QJM | Year: 2011

High uric acid (UA) levels can cause gout, urolithiasis and acute and chronic nephropathy, all of which are due to the deposit of urate crystals. There is also increasing evidence of relationships of hyperuricemia with other important disorders, including hypertension, chronic renal disease, metabolic syndrome and cardiovascular disease, as well as an increased mortality, although a causal relationship between these conditions has not been clearly established. On the other hand, low UA levels are not known to cause any disorder or disease. However, in the last few years a higher prevalence and progression of some neurological diseases have been associated with a low UA, and it is possible that they may predispose to some other disorders, mainly due to the decrease in its antioxidant activity. In this article, the known negative effects of UA are reviewed, as well as the much less-known possible positive actions, and their therapeutic implications. © The Author 2011. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved.

Silva B.M.D.,Complejo Asistencial Universitario | Neves S.J.,Centro Hospitalar Cova da Beira | Martinez A.G.,Complejo Asistencial Universitario | de Jesus Geneux K.,Complejo Asistencial Universitario | And 3 more authors.
GE Portuguese Journal of Gastroenterology | Year: 2016

The recognition of an enteropathy caused by olmesartan is recent. It was first described in 2012 by the Mayo Clinic, which presented 22 clinical cases. Olmesartan is a highly prescribed drug and the differential diagnosis of a sprue-like enteropathy is very wide, so it is important to be aware of this pathology.We report a case of a 67-years-old man, with arterial hypertension under treatment with olmesartan, with a 4-months history of diarrhea and weight lost. He was admitted three times in our Department during this period of time. An initial diagnosis was made of lymphocytic colitis but he did not respond to treatment with corticosteroids. There was a high suspicion of celiac disease, so the patient started a gluten-free diet but still there were no symptomatic changes. The patient underwent several blood and imaging tests which were negative. Due to the suspicion of an enteropathy caused by drugs, olmesartan was stopped and the patient showed a significant improvement of his symptoms.The exact pathophysiology of this entity remains to be elucidated. It may affect all gastrointestinal tract and mimic a refractory celiac disease as well as a lymphocytic colitis due to similar symptoms and histology. It is expected more cases like this in the future due to high use of olmesartan in current clinical practice.So, it is important to all gastroenterologists to be aware of this pathology and take it into consideration when putting together a differential diagnosis. © 2015 Sociedade Portuguesa de Gastrenterologia.

Discover hidden collaborations